Lixte Biotechnology Holdings Announces Increased Funding And FDA ...

News | 01 August 2012

• Print This

EAST SETAUKET, N.Y., July 31, 2012 /PRNewswire/ -- Lixte Biotechnology Holdings, Inc. (LIXT.PK), announced allowance by the Food and Drug Administration to conduct a Phase I trial of its lead, potentially first-in-class, anti-cancer compound, LB-100.

Click on the link to read the full article at Sacramento Bee
(This link will open in a new window)